Exelixis, Inc.
Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients…
Biotechnology
US, Alameda [HQ]
Cash Flow Statements
15 Sheets · Starting from 2023In Million USD. Margins, Growth Rates In %
| Metric | 2009 | 2010 | 2011 | 2012 | 2013 | 2014 | 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Activities | ||||||||||||||||
| Operating Cash Flow (OCF) | -14.00 | -101.00 | -159.00 | -123.00 | -198.00 | -235.00 | -141.00 | 206.00 | 165.00 | 415.00 | 526.00 | 208.00 | 400.00 | 362.00 | 333.00 | |
| Operating Cash (Net) | -14.00 | -101.00 | -159.00 | -123.00 | -198.00 | -235.00 | -141.00 | 206.00 | 165.00 | 415.00 | 526.00 | 208.00 | 400.00 | 362.00 | 333.00 | |
| Accounts Receivable | - - | - - | - - | 27.00 | 8.00 | - - | - - | -37.00 | -40.00 | -85.00 | 43.00 | -42.00 | -122.00 | 66.00 | -22.00 | |
| Accounts Payable | - - | -9.00 | -5.00 | 6.00 | 8.00 | -13.00 | -1.00 | - - | 3.00 | - - | 44.00 | 51.00 | 55.00 | 25.00 | 53.00 | |
|
Working Capital
|
- - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
| Change | 80.00 | -42.00 | -264.00 | -8.00 | -2.00 | -10.00 | -25.00 | 227.00 | -6.00 | -79.00 | 67.00 | -40.00 | -39.00 | -12.00 | -13.00 | |
| Other WC | 80.00 | -32.00 | -259.00 | -14.00 | -16.00 | 3.00 | -23.00 | 264.00 | 34.00 | 8.00 | -15.00 | -26.00 | 41.00 | -93.00 | -31.00 | |
| Investing Activities | ||||||||||||||||
| Used Cash (Net) | -112.00 | -19.00 | -51.00 | -259.00 | 144.00 | 146.00 | 50.00 | -216.00 | 35.00 | -297.00 | -587.00 | -131.00 | -42.00 | -524.00 | -26.00 | |
| Capital Expenditure | -5.00 | -1.00 | - - | -2.00 | -2.00 | - - | - - | -1.00 | -21.00 | -33.00 | -12.00 | -30.00 | -64.00 | -138.00 | -162.00 | |
| Purchases of Investments | -161.00 | -167.00 | -237.00 | -533.00 | -189.00 | -119.00 | -143.00 | -369.00 | -319.00 | -557.00 | -1,182.00 | -1,070.00 | -1,357.00 | -1,450.00 | -902.00 | |
| Sale/Maturity of Investment | 55.00 | 140.00 | 182.00 | 310.00 | 325.00 | 252.00 | 178.00 | 153.00 | 376.00 | 292.00 | 608.00 | 969.00 | 1,378.00 | 1,064.00 | 1,038.00 | |
| Property, Plant, Equipment (P&PE) | -5.00 | -1.00 | - - | -2.00 | -2.00 | - - | - - | -1.00 | -21.00 | -33.00 | -12.00 | -30.00 | -64.00 | -138.00 | -162.00 | |
| Acquisitions (Net) | 2.00 | 9.00 | 3.00 | 1.00 | - - | - - | - - | 2.00 | - - | - - | 12.00 | 100.00 | 66.00 | 138.00 | 40.00 | |
| Other Investing Activities | -2.00 | - - | 1.00 | -35.00 | 11.00 | 12.00 | 15.00 | -1.00 | -1.00 | - - | -12.00 | -100.00 | -66.00 | -138.00 | -40.00 | |
| Financing Activities | ||||||||||||||||
| Used Cash (Net) | -33.00 | -131.00 | -187.00 | -478.00 | -11.00 | -65.00 | -152.00 | -19.00 | -169.00 | -9.00 | -12.00 | -25.00 | -14.00 | - - | -546.00 | |
| Debt Repayment | -43.00 | -39.00 | -8.00 | -4.00 | -13.00 | -11.00 | -4.00 | -7.00 | -185.00 | - - | - - | - - | - - | - - | - - | |
| Dividends Paid | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
|
Common Stock
|
- - | - - | - - | - - | - - | - - | 146 | 31 | 28 | 24 | 32 | 74 | 63 | - - | 612 | |
| Issued | 3.00 | 3.00 | 181.00 | 203.00 | - - | - - | 145.00 | 27.00 | 22.00 | 17.00 | 22.00 | 24.00 | 24.00 | 23.00 | 33.00 | |
| Repurchased | - - | - - | - - | - - | - - | - - | - - | -4.00 | -6.00 | -7.00 | -9.00 | -50.00 | -39.00 | 23.00 | -579.00 | |
| Other Financing Activities | 5.00 | 167.00 | 15.00 | 279.00 | 1.00 | 77.00 | 11.00 | 27.00 | 15.00 | 9.00 | 22.00 | 24.00 | 24.00 | -47.00 | 33.00 | |
| Cash Balances | ||||||||||||||||
| Begin of Period | 247.00 | 86.00 | 97.00 | 74.00 | 170.00 | 103.00 | 80.00 | 141.00 | 151.00 | 188.00 | 315.00 | 268.00 | 320.00 | 663.00 | 502.00 | |
| End of Period | 86.00 | 97.00 | 74.00 | 170.00 | 103.00 | 80.00 | 141.00 | 151.00 | 183.00 | 315.00 | 268.00 | 320.00 | 663.00 | 502.00 | 262.00 | |
| Change | -160.00 | 10.00 | -23.00 | 95.00 | -66.00 | -23.00 | 61.00 | 10.00 | 31.00 | 127.00 | -47.00 | 52.00 | 343.00 | -161.00 | -239.00 | |
| Non-Cash Balances | ||||||||||||||||
| Depreciation and Amortization | 12.00 | 10.00 | 6.00 | 5.00 | 3.00 | 2.00 | 1.00 | 1.00 | 1.00 | 7.00 | 8.00 | 9.00 | 13.00 | 20.00 | 25.00 | |
| Stock Based Compensation | 22.00 | 21.00 | 12.00 | 8.00 | 12.00 | 10.00 | 21.00 | 22.00 | 23.00 | - - | 56.00 | 105.00 | 119.00 | 107.00 | 106.00 | |
| Other | 1.00 | 6.00 | 88.00 | 19.00 | 33.00 | 33.00 | 30.00 | 13.00 | -10.00 | -2.00 | 2.00 | 7.00 | 28.00 | 125.00 | 140.00 | |
| Highlighted metrics | ||||||||||||||||
| Free Cash Flow (FCF) | -20.00 | -102.00 | -160.00 | -125.00 | -200.00 | -235.00 | -142.00 | 204.00 | 144.00 | 382.00 | 514.00 | 178.00 | 336.00 | 224.00 | 170.00 | |
| Cash Conversion Cycle (CCC) | - - | - - | - - | - - | -2,061.00 | -649.00 | -303.00 | -99.00 | -5.00 | 61.00 | 59.00 | 32.00 | 94.00 | 52.00 | -35.00 | |
| Invested Capital | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | |
|
Other Operating Inflows/Outflows
|
||||||||||||||||
| Forex Effect on Cash | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - | - - |